Aplastic Anemia (AA)
Aplastic anemia (AA) is a serious blood system disease. Our company is committed to developing cutting-edge diagnostics and therapeutics for the management of aplastic anemia. As your reliable partner in aplastic anemia research, we offer streamlined and comprehensive solutions to meet all your scientific research requirements.
Overview of Aplastic Anemia
Aplastic anemia is a rare and serious blood disorder characterized by the inability of the bone marrow to produce an adequate number of blood cells and platelets. It poses significant health risks, including increased susceptibility to infections, bleeding issues, and other complications. Left untreated, aplastic anemia can be life-threatening. The incidence of aplastic anemia is approximately 1.5 to 7 cases per million inhabitants per year.
Fig. 1 Possible mechanisms contributing to bone marrow niche modulation and immune destruction of hematopoiesis in acquired aplastic anemia. (Medinger, Michael, et al., 2018)Pathogenesis of Aplastic Anemia
In aplastic anemia, the immune system erroneously attacks the bone marrow, hindering its capacity to generate new blood cells and platelets. This immune-driven destruction causes a reduction in red blood cells, white blood cells, and platelets, leading to the distinctive symptoms associated with aplastic anemia. While the precise cause of aplastic anemia remains incompletely understood, multiple factors contribute to its development.
- Autoimmune diseases cause white blood cells to attack bone marrow
- Viral infections, such as parvovirus, hepatitis, Epstein-Barr virus, cytomegalovirus, and HIV
- Exposure to carcinogens, use of certain drugs, or exposure to radiation
- Inherited bone marrow failure syndromes, such as Fanconi anemia and Shwachman-Diamond syndrome
Types of Aplastic Anemia Therapy
Immunosuppressive Therapy
Immunomodulatory agents, such as ATG and cyclosporine, form the cornerstone of immunosuppressive therapy for aplastic anemia. ATG works by targeting and depleting specific immune cell populations, while cyclosporine suppresses immune responses by inhibiting T-cell activation. This combination therapy has shown efficacy in promoting hematopoietic recovery and improving blood cell counts in aplastic anemia individuals.
Stem Cell Transplantation Therapy
Stem cell transplantation involves replacing the damaged or dysfunctional bone marrow of aplastic anemia individuals with healthy stem cells from compatible donors. Stem cell transplantation provides a source of healthy blood stem cells that can repopulate the bone marrow and restore normal blood cell production. However, this approach is generally reserved for younger individuals and those with severe or refractory aplastic anemia.
Our Services
Our company has established comprehensive platforms for developing rare disease diagnostics and therapies, encompassing small molecule drug, cell therapy, gene therapy, therapeutic antibody, therapeutic peptide, and therapeutic protein. Through our dedicated platforms, we are fully devoted to advancing the development of innovative diagnostic tools and therapies for aplastic anemia.
Recognizing the significance of animal disease models in the therapy development for aplastic anemia, we offer our expertise in establishing animal models specifically tailored for aplastic anemia. These models serve as invaluable tools to facilitate the safety evaluation and pharmacokinetics study of your drug candidates.
Animal Models of Aplastic Anemia
| Immune Induced Models | |||
|---|---|---|---|
| Our scientists administered immune modulators, such as antithymocyte globulin (ATG) or monoclonal antibodies, to animals to destroy hematopoietic stem cells and trigger an immune response, thereby successfully obtaining animal models with aplastic anemia disease characteristics. In addition, we can also induce aplastic anemia models through viral infection, such as parvovirus, hepatitis, Epstein-Barr virus, cytomegalovirus, and HIV. | |||
| Physically or Chemically Induced Models | |||
| Radiation or chemicals can also be used to damage the bone marrow and replicate the bone marrow failure seen in aplastic anemia. For example, our researchers have successfully developed aplastic anemia animal models using toxic chemicals such as benzene, busulfan, and chloramphenicol, as well as radiation from radioactive substances. | |||
| Optional Models |
|
|
|
| Optional Species | Rodents (Mice and Rats), Canines, Pigs, Non-Human Primates (Rhesus Monkeys), Others | ||
Regardless of your current stage of research, we offer comprehensive research services tailored to your needs. If you are interested in our services, please don't hesitate to contact us for more information and a detailed quotation regarding the specific services you require.
References
- Medinger, Michael, et al. "Pathogenesis of acquired aplastic anemia and the role of the bone marrow microenvironment." Frontiers in Oncology 8 (2018): 587.
- Young, Neal S. "Aplastic anemia." New England Journal of Medicine 379.17 (2018): 1643-1656.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.